Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines.

Petrecz M, Acosta CJ, Klopfer SO, Kuter BJ, Goveia MG, Stek JE, Schödel FP, Lee AW.

Hum Vaccin Immunother. 2019;15(2):426-432. doi: 10.1080/21645515.2018.1530934. Epub 2018 Nov 15.

PMID:
30431383
2.

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.

Edwards JE Jr, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, Marchus E, Lizakowski M, DeMontigny EA, Hoeg J, Holmberg T, Cooke MT, Hoover K, Edwards L, Jacobs M, Sussman S, Augenbraun M, Drusano M, Yeaman MR, Ibrahim AS, Filler SG, Hennessey JP Jr.

Clin Infect Dis. 2018 Jun 1;66(12):1928-1936. doi: 10.1093/cid/ciy185.

3.

Clinical development strategy for a candidate group A streptococcal vaccine.

Schödel F, Moreland NJ, Wittes JT, Mulholland K, Frazer I, Steer AC, Fraser JD, Carapetis J.

Vaccine. 2017 Apr 11;35(16):2007-2014. doi: 10.1016/j.vaccine.2017.02.060. Epub 2017 Mar 16. Review.

PMID:
28318768
4.

Status of research and development of vaccines for Streptococcus pyogenes.

Steer AC, Carapetis JR, Dale JB, Fraser JD, Good MF, Guilherme L, Moreland NJ, Mulholland EK, Schodel F, Smeesters PR.

Vaccine. 2016 Jun 3;34(26):2953-2958. doi: 10.1016/j.vaccine.2016.03.073. Epub 2016 Mar 29.

5.

Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.

Mellata M, Mitchell NM, Schödel F, Curtiss R Rd, Pier GB.

Vaccine. 2016 Jan 27;34(5):656-662. doi: 10.1016/j.vaccine.2015.12.014. Epub 2015 Dec 18.

6.

Concomitant use of VAQTA with PedvaxHIB and Infanrix in 12 to 17 month old children.

Petrecz M, Ramsey KP, Stek JE, Martin JC, Klopfer SO, Kuter B, Schödel FP, Lee AW.

Hum Vaccin Immunother. 2016;12(2):503-11. doi: 10.1080/21645515.2015.1080395.

7.

M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.

Wiedmann RT, Reisinger KS, Hartzel J, Malacaman E, Senders SD, Giacoletti KE, Shaw E, Kuter BJ, Schödel F, Musey LK.

Vaccine. 2015 Apr 27;33(18):2132-40. doi: 10.1016/j.vaccine.2015.03.017. Epub 2015 Mar 18.

PMID:
25796337
8.

Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.

Lawrence J, He S, Martin J, Schödel F, Ciarlet M, Murray AV.

Hum Vaccin Immunother. 2014;10(8):2247-54. doi: 10.4161/hv.29107.

9.

Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.

Gilbert CL, Stek JE, Villa G, Klopfer SO, Martin JC, Schödel FP, Bhuyan PK.

Vaccine. 2014 Nov 12;32(48):6521-6. doi: 10.1016/j.vaccine.2014.09.015. Epub 2014 Sep 22.

PMID:
25252192
10.

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).

Klopfer SO, Stek JE, Petrecz M, Reisinger KS, Black SB, Goveia MG, Nicholson O, Gardner JL, Grosso AD, Brown ML, Kuter BJ, Schödel FP.

Vaccine. 2014 Dec 12;32(52):7154-60. doi: 10.1016/j.vaccine.2014.08.067. Epub 2014 Sep 16.

PMID:
25219563
11.

Disupersilylperoxo radical anion [tBu3 SiOOSitBu3 ](⋅-) : an intermediate of supersilanide oxidation.

Budanow A, Haeri HH, Sänger I, Schödel F, Bolte M, Prisner T, Wagner M, Lerner HW.

Chemistry. 2014 Aug 11;20(33):10236-9. doi: 10.1002/chem.201403854. Epub 2014 Jul 14.

PMID:
25042609
12.

Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Kirchmeier M, Fluckiger AC, Soare C, Bozic J, Ontsouka B, Ahmed T, Diress A, Pereira L, Schödel F, Plotkin S, Dalba C, Klatzmann D, Anderson DE.

Clin Vaccine Immunol. 2014 Feb;21(2):174-80. doi: 10.1128/CVI.00662-13. Epub 2013 Dec 11.

13.

Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.

Yetman RJ, Shepard JS, Duke A, Stek JE, Petrecz M, Klopfer SO, Kuter BJ, Schödel FP, Lee AW.

Hum Vaccin Immunother. 2013 Aug;9(8):1691-7. doi: 10.4161/hv.24873. Epub 2013 Jun 6.

14.

Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.

Iwata S, Nakata S, Ukae S, Koizumi Y, Morita Y, Kuroki H, Tanaka Y, Shizuya T, Schödel F, Brown ML, Lawrence J.

Hum Vaccin Immunother. 2013 Aug;9(8):1626-33. doi: 10.4161/hv.24846. Epub 2013 May 31.

15.

Group A streptococcal vaccines: paving a path for accelerated development.

Dale JB, Fischetti VA, Carapetis JR, Steer AC, Sow S, Kumar R, Mayosi BM, Rubin FA, Mulholland K, Hombach JM, Schödel F, Henao-Restrepo AM.

Vaccine. 2013 Apr 18;31 Suppl 2:B216-22. doi: 10.1016/j.vaccine.2012.09.045. Review.

PMID:
23598485
16.

Boron-doped tri(9,10-anthrylene)s: synthesis, structural characterization, and optoelectronic properties.

Hoffend C, Schödel F, Bolte M, Lerner HW, Wagner M.

Chemistry. 2012 Nov 26;18(48):15394-405. doi: 10.1002/chem.201202280. Epub 2012 Oct 29.

PMID:
23108703
17.

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.

Minervini G, McCarson BJ, Reisinger KS, Martin JC, Stek JE, Atkins BM, Nadig KB, Liska V, Schödel FP, Bhuyan PK.

Vaccine. 2012 Feb 14;30(8):1476-80. doi: 10.1016/j.vaccine.2011.12.095. Epub 2012 Jan 5.

PMID:
22227229
18.

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.

Gilbert CL, Klopfer SO, Martin JC, Schödel FP, Bhuyan PK.

Hum Vaccin. 2011 Dec;7(12):1336-42. doi: 10.4161/hv.7.12.18333. Epub 2011 Dec 1.

PMID:
22185811
19.

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.

Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL.

Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7.

PMID:
22154769
20.

Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children.

Leonardi M, Bromberg K, Baxter R, Gardner JL, Klopfer S, Nicholson O, Brockley M, Trammel J, Leamy V, Williams W, Kuter B, Schödel F.

Pediatrics. 2011 Dec;128(6):e1387-94. doi: 10.1542/peds.2010-2132. Epub 2011 Nov 28.

PMID:
22123890
21.

Immunological Correlates of Vaccine-Derived Protection Fondation Mérieux Conference Center 'Les Pensières' Veyrier-Du-Lac, France, Sept. 20-22, 2010.

Schödel F.

Vaccine. 2011 Dec 6;29(52):9575-7. doi: 10.1016/j.vaccine.2011.10.046. Epub 2011 Oct 30. No abstract available.

PMID:
22041303
22.

Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.

Lee AW, Vesikari T, Gilbert CL, Klopfer SO, Schödel FP, Bhuyan PK.

Vaccine. 2011 Oct 19;29(45):7942-8. doi: 10.1016/j.vaccine.2011.08.071. Epub 2011 Aug 27.

PMID:
21875633
23.

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.

Vesikari T, Martin JC, Liss CL, Liska V, Schödel FP, Bhuyan PK.

Pediatr Infect Dis J. 2011 Jul;30(7):e109-13. doi: 10.1097/INF.0b013e31821ed1a4.

PMID:
21552183
24.

A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series.

Diez-Domingo J, Flores SA, Martin JC, Klopfer SO, Schödel FP, Bhuyan PK.

Pediatr Infect Dis J. 2010 Oct;29(10):972-4. doi: 10.1097/INF.0b013e3181f1b3b6.

PMID:
20724955
25.

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.

Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, Neuzil KM, Ciarlet M.

Lancet. 2010 Aug 21;376(9741):615-23. doi: 10.1016/S0140-6736(10)60755-6. Epub 2010 Aug 6.

PMID:
20692031
26.

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.

Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM.

Lancet. 2010 Aug 21;376(9741):606-14. doi: 10.1016/S0140-6736(10)60889-6. Epub 2010 Aug 6.

PMID:
20692030
27.

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.

Ciarlet M, Schödel F.

Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. doi: 10.1016/j.vaccine.2009.09.107. Review.

PMID:
20006144
28.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

29.

Electronic communication in oligonuclear ferrocene complexes with anionic four-coordinate boron bridges.

Kaufmann L, Breunig JM, Vitze H, Schödel F, Nowik I, Pichlmaier M, Bolte M, Lerner HW, Winter RF, Herber RH, Wagner M.

Dalton Trans. 2009 Apr 28;(16):2940-50. doi: 10.1039/b821406a. Epub 2009 Feb 27.

PMID:
19352521
30.

Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults.

Wallace M, Evans B, Woods S, Mogg R, Zhang L, Finnefrock AC, Rabussay D, Fons M, Mallee J, Mehrotra D, Schödel F, Musey L.

Mol Ther. 2009 May;17(5):922-8. doi: 10.1038/mt.2009.27. Epub 2009 Mar 10.

31.

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.

Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schödel F.

Pediatr Infect Dis J. 2009 Mar;28(3):177-81. doi: 10.1097/INF.0b013e31818c0161.

PMID:
19209092
32.

Supersilylated tetraphosphene derivatives M2[t-Bu3SiPPPPSi-t-Bu3] (M = Li, Na, Rb, Cs) and Ba[t-Bu3SiPPPPSi-t-Bu3]: reactivity and cis-trans isomerization.

Lorbach A, Nadj A, Tüllmann S, Dornhaus F, Schödel F, Sänger I, Margraf G, Bats JW, Bolte M, Holthausen MC, Wagner M, Lerner HW.

Inorg Chem. 2009 Feb 2;48(3):1005-17. doi: 10.1021/ic8016003.

PMID:
19105734
33.

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.

Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM, Gottesdiener KM, Arredondo JL, Schödel F.

Pediatr Infect Dis J. 2008 Oct;27(10):874-80. doi: 10.1097/INF.0b013e3181782780.

PMID:
18756184
34.

Isoelectronic caesium compounds: the triphosphenide Cs[tBu3SiPPPSitBu3] and the enolate Cs[OCH=CH2].

Lerner HW, Sänger I, Schödel F, Lorbach A, Bolte M, Wagner M.

Dalton Trans. 2008 Feb 14;(6):787-92. doi: 10.1039/b714339g. Epub 2007 Nov 29.

PMID:
18239834
35.

A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, Azrolan N, Sutradhar SC, Wang WW, Chan IS, Schlienger K, Schödel F, Silber JL; Zostavax Protocol 010 Study Group.

Clin Vaccine Immunol. 2008 Feb;15(2):314-9. Epub 2007 Dec 12.

36.

Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.

Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.

J Am Geriatr Soc. 2007 Oct;55(10):1499-507.

PMID:
17908055
37.

Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine.

Stojanov S, Liese JG, Belohradsky BH, Vandermeulen C, Hoppenbrouwers K, Van der Wielen M, Van Damme P, Georges B, Dupuy M, Scemama M, Watson M, Fiquet A, Stek JE, Golm GT, Schödel FP, Kuter BJ; HEXAVAC/VAQTA Study Group.

Vaccine. 2007 Oct 23;25(43):7549-58. Epub 2007 Sep 4.

PMID:
17905486
38.

Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine.

Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weinberg A.

Vaccine. 2007 Oct 10;25(41):7087-93. Epub 2007 Aug 15.

PMID:
17766015
39.

Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).

Bernstein HH, Eves K, Campbell K, Black SB, Twiggs JD, Reisinger KS, Conti RM, Flodmark CE, Rombo L, Klopfer S, Schödel F, Hartzel J, Kuter BJ; Refrigerator-Stable Formulation Study Group for ProQuad.

Pediatrics. 2007 Jun;119(6):e1299-305. Epub 2007 May 14.

PMID:
17502347
40.

Second varicella vaccine dose.

Kuter B, Schodel F.

Pediatr Infect Dis J. 2007 Feb;26(2):193-4. No abstract available.

PMID:
17259894
41.

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.

Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, Meechan C, Li D, Schlienger K, Chan I, Sadoff J, Schödel F, Silber JL.

Vaccine. 2007 Mar 1;25(11):2139-44. Epub 2006 Nov 27.

PMID:
17250932
42.

large-scale serologic testing program to assess the immunogenicity of inactivated hepatitis a vaccine (VAQTA) in prefilled syringes following product recall in Germany.

Jäger G, Kuter B, Campe H, Lakkis H, Nitschko H, Watson M, Harzer E, Schödel F.

Hum Vaccin. 2006 Nov-Dec;2(6):233-6. Epub 2006 Nov 2.

PMID:
17204866
43.

Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.

Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL, Harmon A, Chalikonda I, Smith JG, Stek JE, Robertson A, Caulfield MJ, Biasio LR, Silber JL, Chan CY, Vessey R, Sadoff J, Chan IS, Matthews H, Wang W, Schlienger K, Schödel FP; Protocol 049 Study Group.

Vaccine. 2006 Nov 17;24(47-48):6875-85. Epub 2006 Jul 7.

PMID:
17050042
44.

Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).

Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, Thear M, Klopfer S, Xu J, Gress JO, Schödel F; Study Group for ProQuad.

Hum Vaccin. 2006 Sep-Oct;2(5):205-14.

PMID:
17035730
45.
46.

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Jul;25(7):615-22.

PMID:
16804432
47.

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM.

Vaccine. 2006 May 29;24(22):4821-9. Epub 2006 Mar 31.

PMID:
16621194
48.

Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.

Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B; 013 Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Apr;25(4):287-92.

PMID:
16567978
49.

A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.

Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad.

Pediatrics. 2006 Feb;117(2):265-72. Erratum in: Pediatrics. 2006 Jun;117(6):2338.

PMID:
16452343
50.

Comparative antigenicity and immunogenicity of hepadnavirus core proteins.

Billaud JN, Peterson D, Schödel F, Chen A, Sallberg M, Garduno F, Goldstein P, McDowell W, Hughes J, Jones J, Milich D.

J Virol. 2005 Nov;79(21):13641-55.

Supplemental Content

Loading ...
Support Center